July 25, 2018
KLEBVax SRP: First ever Klebsiella mastitis licensed-vaccine for dairy cattle
Dairy producers and veterinarians now have an additional prevention and reduction tool in antibiotic use as AgriLabs announced the debut of the KELBVax SRP vaccine this week.
It is the first licensed vaccine for dairy cattle to prevent mastitis caused by Klebsiella pneumonia.
A similar autogenous product was offered by AgriLabs in partnership with Epitopix that used a bacterial extract of Klebsiella SRP.
"Klebsiella is a widespread pathogen that has been difficult to prevent in dairy operations and has cost producers significant losses," Sean O'Hare, executive vice president for AgriLabs said.
"We are excited to offer KLEBVax SRP to veterinarians and dairy producers as a new management tool to reduce the occurrence of Klebsiella mastitis. As a vaccine, KLEBVax SRP will provide an alternative to antibiotics and help shift the focus from treatment to prevention."
According to a field study by Iowa State University, using KELBVax SRP showed a 71% reduction in infection within 90 days of calving versus a placebo group. Other benefits include a 42% reduction in somatic cell count and an increase of 2lbs in milk production, per cow/per day.
The new vaccine activates the animal's immune system to produce antibodies that bind and block the transfer of iron through bacterial cell wall porins. Gram-negative bacteria such as Klebsiella require an iron for growth and survival, therefore, the vaccine helps to deprive the bacteria of nutrients.
Jim Sandstrom, DVM, managing director of Epitopix, LLC, stated, "The unique process of the SRP technology makes it well-suited for the challenges associated with the disease, which causes bacteria such as Klebsiella."
"With several years of field experience with autogenous Klebsiella SRP vaccines, we are confident the new KLEBVax SRP product will help dairy veterinarians and producers manage mastitis infections caused by Klebsiella," Sandstrom added.